Relapsed Refractory Multiple Myeloma (RRMM), Teclistamab+Daratumumab, Daratumumab+Pomalidomide+Dexamethasone (DPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd), Phase 3, 1,2,3 prior line of therapy, B-Cell Maturation Antigens (BCMA) Bispecific Antibody, Lenalidomide Exposed, Lenalidomide Refractory
### Instruction:
Identify the study with the following condition. 
### Input:
Relapsed Refractory Multiple Myeloma (RRMM), Teclistamab+Daratumumab, Daratumumab+Pomalidomide+Dexamethasone (DPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd), Phase 3, 1,2,3 prior line of therapy, B-Cell Maturation Antigens (BCMA) Bispecific Antibody, Lenalidomide Exposed, Lenalidomide Refractory 
### Output:
Popular Name is MajesTEC-3, Study ID is NCT05083169